Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations?
Empana JP; Ducimetire P; Arveiler D; Ferrires J; Evans A; Ruidavets JB; Haas B; Yarnell J; Bingham A; Amouyel P; Dallongeville J; Lille MONICA Project, INSERM U508, Institut Pasteur de Lille, Lille, France. empana@vjf.inserm.fr AIMS: To assess whether the Framingham and PROCAM risk functions were applicable to men in Belfast and France. METHODS AND RESULTS: We performed an external validation study within the PRIME (Prospective Epidemiological Study of Myocardial Infarction) cohort study. It comprised men recruited in Belfast (2399) and France (7359) who were aged 50 to 59 years, free of CHD at baseline (1991 to 1993) and followed over 5 years for CHD events (coronary death, myocardial infarction, angina pectoris). We compared the relative risks of CHD associated with the classic risk factors in PRIME with those in Framingham and PROCAM cohorts. We then compared the number of predicted and observed 5-year CHD events (calibration). Finally, we estimated the ability of the risk functions
